BUSINESS PROFILE :
Sun Pharma is into speciality pharmaceuticals and active pharmaceutical ingredients. The company operates in select therapeutic segments like psychiatry, neurology, cardiology and gastro-enterology. As many as 8 bulk actives and 18 processes for DMFs have been developed and scaled up. In all, the company has received 7 DMFs and 9 EDMFs.
The company doubled its capacity and the area at the bulk active site in Panoli. With the completion of this expansion, 269,000 sq ft area has been added to the plant thereby offering additional 129 KL reactor capacity for the regulated markets.
The company plans to work on various technologies in NDDS and work on specific therapy areas for NCE. For products that are differentiated for the medium term, it would continue to work on technologically complex products such as liposome delivery systems, microspheres based delivery systems and controlled release technologies.
|